By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Boehringer Ingelheim Corporation 

P.O. Box 368
900 Ridgebury Road
Ridgefield  Connecticut  06877-0368  U.S.A.
Phone: 203-798-99-88 Fax: 203-791-62-34


Company News
Boehringer Ingelheim Submits Biologics License Application To FDA For Idarucizumab, Investigational Specific Reversal Agent For Pradaxa (Dabigatran Etexilate Mesylate) 3/2/2015 7:34:49 AM
Boehringer Ingelheim and Vitae Pharmaceuticals, Inc. (VTAE) Release: BACE Inhibitor BI 1181181 Voluntarily Put On Temporary Clinical Hold For Safety Evaluation 2/27/2015 7:04:45 AM
Boehringer Ingelheim Puts Hold on Key Alzheimer's Drug Trial 2/27/2015 7:00:54 AM
Boehringer Ingelheim Corporation Release: New Phase 2 Data In Asthma Patients Show Tiotropium Improves Lung Function, Regardless Of Allergic Status 2/23/2015 6:45:11 AM
Boehringer Ingelheim Corporation Selects Genedata Biologics As Antibody Discovery Workflow Platform 2/18/2015 8:17:28 AM
USHCC Applauds Boehringer Ingelheim Corporation For Launch Of Hispanic Health Program 2/17/2015 7:34:29 AM
Boehringer Ingelheim Corporation Cuts More Jobs in the U.S. 2/17/2015 6:54:43 AM
Boehringer Ingelheim Corporation Renews Global Technology Collaboration Agreement With VTU Technology 2/10/2015 8:53:22 AM
Boehringer Ingelheim Corporation Release: New Large-Scale Study To Investigate Effect Of Tiotropium + Olodaterol Respimat® On Exacerbations In COPD 1/27/2015 10:37:33 AM
Boehringer Ingelheim Corporation Release: OFEV® (Nintedanib*) Approved In The EU For The Treatment Of IPF 1/19/2015 11:17:46 AM